Answers are grounded in this paper and cite their sources.
New options for RSV prevention are available for the 2023/2024 RSV season, nirsevimab, a monocolonal antibody, and RSVpreF maternal vaccine, that target infants entering their first RSV season. Countries vary in implementation of one or both strategies to reduce the RSV burden among infants.
No takes yet. Share an insight, caveat, or question.
Suss et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: